Fifth Third Bancorp reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 793,885 shares of the biopharmaceutical company’s stock after selling 19,542 shares during the quarter. Fifth Third Bancorp owned about 0.06% of Gilead Sciences worth $61,296,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in GILD. American Money Management LLC raised its position in Gilead Sciences by 1.7% during the 3rd quarter. American Money Management LLC now owns 59,353 shares of the biopharmaceutical company’s stock worth $4,583,000 after buying an additional 988 shares during the last quarter. CapWealth Advisors LLC raised its position in Gilead Sciences by 1.2% during the 3rd quarter. CapWealth Advisors LLC now owns 127,564 shares of the biopharmaceutical company’s stock worth $9,849,000 after buying an additional 1,521 shares during the last quarter. King Luther Capital Management Corp raised its position in Gilead Sciences by 12.3% during the 3rd quarter. King Luther Capital Management Corp now owns 9,125 shares of the biopharmaceutical company’s stock worth $705,000 after buying an additional 1,000 shares during the last quarter. WEALTHFRONT Corp raised its position in Gilead Sciences by 6.9% during the 3rd quarter. WEALTHFRONT Corp now owns 18,382 shares of the biopharmaceutical company’s stock worth $1,419,000 after buying an additional 1,193 shares during the last quarter. Finally, Woodley Farra Manion Portfolio Management Inc. raised its position in Gilead Sciences by 0.4% during the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 365,540 shares of the biopharmaceutical company’s stock worth $28,223,000 after buying an additional 1,350 shares during the last quarter. 78.19% of the stock is owned by hedge funds and other institutional investors.

In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $239,408,146.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 150,000 shares of company stock valued at $10,939,500. Insiders own 1.30% of the company’s stock.

A number of equities analysts have issued reports on the stock. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Finally, Mizuho reissued a “buy” rating and set a $94.00 price target on shares of Gilead Sciences in a research report on Friday, August 10th. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $88.63.

NASDAQ:GILD opened at $70.19 on Friday. The company has a quick ratio of 3.37, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. The company has a market cap of $89.97 billion, a PE ratio of 8.20, a PEG ratio of -2.70 and a beta of 1.01. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the previous year, the firm earned $2.27 EPS. Analysts expect that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-sold-by-fifth-third-bancorp/2667398.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Read More: What are catch-up contributions?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.